[go: up one dir, main page]

EA038828B9 - Фармацевтическая композиция, содержащая действенный ингибитор urat1 - Google Patents

Фармацевтическая композиция, содержащая действенный ингибитор urat1

Info

Publication number
EA038828B9
EA038828B9 EA201891267A EA201891267A EA038828B9 EA 038828 B9 EA038828 B9 EA 038828B9 EA 201891267 A EA201891267 A EA 201891267A EA 201891267 A EA201891267 A EA 201891267A EA 038828 B9 EA038828 B9 EA 038828B9
Authority
EA
Eurasian Patent Office
Prior art keywords
urat1
pharmaceutical composition
potent inhibitor
compositions
agent
Prior art date
Application number
EA201891267A
Other languages
English (en)
Other versions
EA201891267A1 (ru
EA038828B1 (ru
Inventor
Джоэнн Рейланд Уэйкмэн
Колин Роулингз
Ша Лю
Джерри Бёрк
Кристиан Фон Корсвант
Кристер Таннергрен
Йохан Йерстам
Original Assignee
Ардеа Байосаенсез, Инк.
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57517882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA038828(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ардеа Байосаенсез, Инк., Астразенека Аб filed Critical Ардеа Байосаенсез, Инк.
Publication of EA201891267A1 publication Critical patent/EA201891267A1/ru
Publication of EA038828B1 publication Critical patent/EA038828B1/ru
Publication of EA038828B9 publication Critical patent/EA038828B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к фармацевтическим композициям, содержащим 2-((3-(4-цианонафталин-1-ил)пиридин-4-ил)тио)-2-метилпропановую кислоту или фармацевтически приемлемую соль (далее в настоящем документе именуемые "средством"), в частности к доставляемым пероральным путем композициям, содержащим средство; к применению указанных композиций в качестве лекарственного препарата и к способам получения указанных композиций.
EA201891267A 2015-12-08 2016-12-07 Фармацевтическая композиция, содержащая действенный ингибитор urat1 EA038828B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264792P 2015-12-08 2015-12-08
PCT/EP2016/080111 WO2017097845A1 (en) 2015-12-08 2016-12-07 Pharmaceutical composition comprising a potent inhibitor of urat1

Publications (3)

Publication Number Publication Date
EA201891267A1 EA201891267A1 (ru) 2019-01-31
EA038828B1 EA038828B1 (ru) 2021-10-26
EA038828B9 true EA038828B9 (ru) 2021-12-03

Family

ID=57517882

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891267A EA038828B9 (ru) 2015-12-08 2016-12-07 Фармацевтическая композиция, содержащая действенный ингибитор urat1

Country Status (20)

Country Link
US (3) US20180360761A1 (ru)
EP (1) EP3386485A1 (ru)
JP (2) JP6976946B2 (ru)
KR (1) KR20180082613A (ru)
CN (1) CN108289848A (ru)
AU (1) AU2016368622B2 (ru)
BR (1) BR112018011376A2 (ru)
CA (1) CA3006167A1 (ru)
CL (1) CL2018001510A1 (ru)
CO (1) CO2018005842A2 (ru)
EA (1) EA038828B9 (ru)
HK (2) HK1253034A1 (ru)
IL (1) IL259844B (ru)
MA (1) MA43402A (ru)
MX (1) MX394588B (ru)
PE (1) PE20181521A1 (ru)
PH (1) PH12018501236A1 (ru)
SG (1) SG11201804100UA (ru)
WO (1) WO2017097845A1 (ru)
ZA (1) ZA201804519B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6025853B2 (ja) * 2011-11-03 2016-11-16 アルデア バイオサイエンシーズ インク． ３，４−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
EP3860601A1 (en) * 2018-10-01 2021-08-11 Astrazeneca AB Compositions for reducing serum uric acid
CN112057429B (zh) * 2019-06-11 2023-04-07 上海京新生物医药有限公司 雷西纳德控释药物组合物
CN114126610A (zh) * 2019-07-16 2022-03-01 阿斯利康(瑞典)有限公司 含维立诺雷的抗剂量倾泻药物配制品
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
CN113368073A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的药物制剂的方法
CN113368067A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的口服药物片剂的方法
WO2022162021A1 (en) 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use
AU2021464980A1 (en) * 2021-09-17 2024-05-02 Hinova Pharmaceuticals Inc. Quinoline compound sustained-release tablet and preparation method therefor
JP7515533B2 (ja) * 2022-04-28 2024-07-12 沢井製薬株式会社 デスロラタジン含有フィルムコーティング錠剤
CA3268994A1 (en) * 2022-10-04 2024-04-11 Engrail Therapeutics, Inc. GABAA RECEIVER MODULATORS AND THEIR USES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
CN101119709A (zh) * 2005-02-15 2008-02-06 惠氏公司 口服生物有效的cci-779配方
CN101252917A (zh) * 2005-07-28 2008-08-27 夏尔有限责任公司 适于每日以单剂量形式给药的胍法辛药物制剂/组合物
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
WO2011126852A2 (en) * 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Treatment of gout
LT2582683T (lt) * 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP6025853B2 (ja) * 2011-11-03 2016-11-16 アルデア バイオサイエンシーズ インク． ３，４−二置換ピリジン化合物、その使用方法、および、該化合物を含む組成物

Also Published As

Publication number Publication date
US20230011269A1 (en) 2023-01-12
JP2019501895A (ja) 2019-01-24
CA3006167A1 (en) 2017-06-15
CN108289848A (zh) 2018-07-17
EA201891267A1 (ru) 2019-01-31
PE20181521A1 (es) 2018-09-24
EA038828B1 (ru) 2021-10-26
CO2018005842A2 (es) 2018-07-10
HK1256256A1 (zh) 2019-09-20
BR112018011376A2 (pt) 2018-12-04
MX2018006903A (es) 2018-11-09
SG11201804100UA (en) 2018-06-28
IL259844A (en) 2018-07-31
EP3386485A1 (en) 2018-10-17
PH12018501236A1 (en) 2019-02-18
JP6976946B2 (ja) 2021-12-08
MA43402A (fr) 2018-10-17
WO2017097845A1 (en) 2017-06-15
MX394588B (es) 2025-03-24
ZA201804519B (en) 2022-04-28
US20210113472A1 (en) 2021-04-22
JP2022033758A (ja) 2022-03-02
CL2018001510A1 (es) 2018-09-21
AU2016368622B2 (en) 2022-09-08
US20180360761A1 (en) 2018-12-20
KR20180082613A (ko) 2018-07-18
HK1253034A1 (zh) 2019-06-06
AU2016368622A1 (en) 2018-06-07
IL259844B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MY183536A (en) Pharmaceutical compositions comprising azd9291
EP4609866A3 (en) Oxysterols and methods of use thereof
HK1244708A1 (zh) 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
HK1255500A1 (zh) 氧固醇及其使用方法
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
PH12016502246A1 (en) Carboxamide derivatives
TN2016000491A1 (en) Carboxamide derivatives.
EP3248603A4 (en) Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient
HK1254636A1 (zh) 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
PH12020500120A1 (en) Pharmaceutical compositions
PH12016502247A1 (en) Carboxamide derivatives
MX2017000580A (es) Agente profilactico o terapeutico para enfermedades del segmento posterior del ojo.
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent